Background: Indication bias is the major challenge in assessing treatment effectiveness in observational studies. We explored the potential advantages of using an instrumental variable approach in the context of primary androgen deprivation therapy (ADT) for prostate cancer.
T here has been considerable interest in recent times in comparative effectiveness research, which aims to identify the optimal management for a given condition. 1 Although clinical trials represent the gold standard for determining the efficacy of treatments, they often lack generalizability because of highly selected enrolled populations. This issue may be potentially addressed with observational study designs, but a major challenge is indication bias. [2] [3] [4] Standard methods such as stratification, matching, multivariable regression, and propensity score approaches often inadequately control for this typically very strong bias. 4, 5 Instrumental variable analysis is a technique borrowed from econometrics that shows promise in health-care settings. 6, 7 The idea entails finding a variable, the instrument, that is strongly associated with a patient's likelihood for receiving treatment, but is independent of the outcome. One of the main challenges is finding a suitable instrument, with geographic region being one of the most commonly used. 5, 8, 9 These studies capitalized on the fact that prognostic factors that relate to outcome are usually evenly distributed across regions, despite often marked differences in rates of treatment. The most frequently used estimation method for these analyses is a 2-stage linear regression to estimate the effect of treatment. 5, [10] [11] [12] [13] However, this method has several disadvantages. Mortality is treated as a continuous, rather than binary variable, potentially resulting in model misspecification and an inconsistent estimate of treatment effect. 14 The results from the model are specified as a risk difference rather than as a relative measure of treatment effect (ie, relative risk or hazard ratio), which may be more desirable. Moreover, only mortality at a specific time point can be analyzed such that patients without complete follow-up are excluded. Therefore, without a censoring mechanism, cause-specific mortality cannot be analyzed.
In this paper, we explored the potential advantages of using an instrumental variable approach for the assessment of primary androgen deprivation therapy (ADT) for prostate cancer. Despite its very common use, substantial controversy remains about ADT, particularly for localized disease, because of a dearth of supporting evidence on efficacy and concerns about serious adverse effects. [15] [16] [17] [18] The uncertainty about ADT resulted in substantial variations in its use across regions and physicians through the 1990s, which we leveraged to construct instruments on the basis of region and physician's prescribing preference. 19, 20 Previous observational studies have paradoxically demonstrated an increased risk of prostate cancer-related death associated with use of ADT. 4, [21] [22] [23] This may represent inadequately controlled bias because the indication for use of ADT usually relates to high-risk characteristics of the prostate tumor. We hypothesized that an instrumental variable approach would provide better control for this type of bias over standard multivariable regression methods. We therefore used instrumental variable analysis, with an alternative estimation method-exogenous probit modeling 14 -to specifically examine the effect of ADT on prostate cancer-specific mortality.
METHODS

Data Sources
We used the merged Surveillance, Epidemiology and End Results (SEER)-Medicare database for the study analyses. The SEER program is overseen by the National Cancer Institute; it consists of regional and state-based tumor registries located throughout the country and represented approximately 14% of the US population until 2001 and 26% thereafter. The American Medical Association Physician Masterfile was used to identify physicians with urology as their primary specialty.
Study Subjects
All men aged 66 years with a diagnosis of incident prostate cancer from 1992 through to 2002 were initially selected for the study (n = 163,613). Follow-up was available up to the end of 2005. To ensure complete information, patients not enrolled in both Medicare part A and part B for 12 months before and 6 months after their cancer diagnosis, who died within 6 months of diagnosis, were members of a health maintenance organization, or were diagnosed at autopsy or on a death certificate were excluded (n = 56,993). Because the focus of the study was use of primary ADT (ie, use of ADT in the absence of other therapies), patients receiving radiation or radical prostatectomy within 6 months of diagnosis were excluded (n = 61,735). To perform the instrumental variable analyses, we identified a treating urologist for each patient using previously described algorithms (n = 10,994 patients who could not be assigned to a urologist were excluded from analyses). 24 
Variables
Patient demographic and tumor characteristics were derived from SEER records and used to categorize patients by age, ethnicity, SEER region of residence, year of diagnosis, clinical stage (T1 through T4), and grade (low: Gleason 2-4; moderate: Gleason 5-7; high: Gleason 8-10). The socioeconomic characteristics of each patient were based on percentage of adults with <12 years of education and median household income within the zip code of residence using US Census 2000 data. Comorbidity was assessed using an adaptation of the Charlson Comorbidity Index for use with claims data. 25, 26 Use of ADT was defined on the basis of the receipt of at least 1 dose of a gonadotropinreleasing hormone agonist or orchiectomy occurring within 6 months of diagnosis, using previously published and validated methods. 18, 22 Two instrumental variables were constructed. The first was based on the geographic region of the patient's residence, using health service area (HSA). An HSA is defined as 1 or more counties that are relatively self-contained with respect to hospital care. There were a total of 81 HSAs for the study cohort [n<11 (precise number suppressed for confidentiality) patients with missing HSA information were excluded]. The variable was constructed as the proportion of patients receiving primary ADT over the study period within each HSA. The second instrumental variable was based on urologist preference for use of primary ADT. Similar to a previous conceptualization, a patient was classified as having a urologist with preference for primary ADT if the urologist had administered primary ADT to any of his or her patients in the most recent previous month. 10 This variable was focused on urologists, as it was noted that, over the study period, the vast majority of ADTs were administered by urologists. 20 Patients diagnosed under the urologist's first prescription month during the study period were excluded (n = 1947).
The outcome variable was overall mortality and causespecific mortality (divided as prostate cancer-specific and nonprostate cancer mortality), obtained from SEER records.
Statistical Analyses
Demographic and tumor characteristics were stratified by whether or not patients had received primary ADT. The same stratification was also performed on the basis of the instrumental variables-whether patients resided in an HSA with a rate of primary ADT use above or below the median (44%) or whether or not patients were assigned a urologist with a preference for use of primary ADT. Standard survival analyses were carried out using Cox proportional hazard regression adjusted for stage, grade, year of diagnosis, age, comorbidity, ethnicity, marital status, SEER region, education, and income. Patients were censored at death or at the end of the study (December 31, 2005) . For comparability to the instrumental variable analyses (see below), patient record data were converted to person-month data, in which each patient had multiple records and was coded as 0 if alive or as 1 if dead, for each month. The total number of records for each patient was equal to the number of months of follow-up with the same censoring as the Cox model above. Unlike survival data analyses, analyses on person-month data do not take into account that the outcome at a given month is conditional on the outcome in previous months. To compare the results between the 2 different approaches, we conducted multivariable probit regression models on the person-month data with the same adjustments as for the Cox model above, with relative risks estimated by multiplying the probit coefficients by a factor of 1.8 to approximate logistic coefficients (a factor of 1.6 is also suggested in the literature but did not alter findings enough to change conclusions; hence, data were not presented). 14, 27 For the instrumental variable analyses, we used an exogenous probit model to analyze person-month data. The standard error of the instrumental variable parameter is estimated robustly to account for intrapatient correlation across months. This method follows the properties of a binary distribution for the outcome of mortality, incorporates a mechanism for censoring, and provides a relative estimate of treatment effect. The equation differs from the 2-stage linear regression approach typically used for instrumental variable analysis, and is listed below:
is observed treatment (an endogenous factor), which can be characterized by a latent variable of T i * and linearly depends on an instrument variable of Z i (an exogenous factor), other risk factors-a vector of X i , and a random error of U 1i . Y i is the study outcome and F is the standard normal distribution function with density f = F 0 . All parameters in the model are maximum likelihood estimators. Each of the instrumental variables was analyzed in different exogenous probit models using the same adjustments as in the Cox proportional hazard model described above.
To test the assumption that the instrumental variables were strongly associated with receipt of ADT, we used a partial F test that has as its null hypothesis the coefficient for the effect of the instrument in the first-stage regression model as zero. 12 For both instruments, the null hypothesis was rejected at P < 0.001, with F statistics of 363 and 939 for HSA and urologist preference, respectively. Generally, an F statistic >10 suggests that the instrument is not weak. 28 To assess the degree to which the instruments were successful in balancing prognostic factors, we developed a prostate cancer severity index using a Cox proportional hazard regression model to predict 1-year and 5-year prostate cancer-specific mortality using baseline patient and tumor characteristics (c statistics = 0.77 and 0.51, respectively) 29 and compared this across levels of the instruments. We also prespecified 2 clinically relevant subgroup analyses. Accordingly, all analyses were repeated for 2 subcohorts. One cohort included patients with lower-risk disease (clinical stage T1 or T2 tumors with low to moderate grade histology) who would be expected to derive minimal benefit from ADT. The other cohort included patients with higher-risk disease (either patients with high-risk clinically localized disease or those with locally advanced disease) who would be expected to benefit from primary ADT. The high-risk clinically localized disease group included patients with clinical stage T1 or T2 tumors but with high-grade histology or T3a tumors. The locally advanced group included patients with T3b tumors or with T4 tumors excluding cases with positive lymph nodes, unknown lymph node status, or distant metastases (n = 3385 patients excluded). All analyses were carried out using SAS v.9.1 (SAS Institute, Cary, NC) and STATA 9.2 (StataCorp, College Station, TX). All statistical tests were 2-sided, with P < 0.05 considered to be statistically significant. The study was approved by the Institutional Review Board of the University of Michigan. Table 1 presents patient and tumor characteristics, as well as predicted 1-year, 5-year prostate cancer-specific mortality, stratified by receipt of primary ADT and by the instrumental variables. Patients who received primary ADT were older and had more advanced-stage and higher-grade prostate tumors. In contrast, across categories of both instrumental variables, there was a substantially more balanced distribution of age, clinical stage, and tumor grade. Crude overall, prostate cancer-specific, and nonprostate cancer survival rates across various time points were substantially lower, and predicted 1-year and 5-year prostate cancerspecific mortality rates were higher, in primary ADT users versus nonusers. In contrast, crude survival and predicted mortality were well balanced across categories of the instrumental variables. Table 2 presents the association between use of primary ADT and overall, prostate cancer-specific and nonprostate cancer mortality, using standard multivariable regression and instrumental variable approaches in the entire cohort of patients. In the multivariable regression models, there was a substantial and significant increase in the risk of prostate cancer-specific mortality associated with use of primary ADT, with more modest but still significant increases in the risk of overall and nonprostate cancer mortality. In contrast, there was a complete reversal of the pattern with prostate cancer-specific mortality with the instrumental variable approaches, with a lower marginal risk associated with either residing in an HSA with a higher primary ADT use or being seen by a urologist with a preference for primary ADT. However, the results were statistically significant only for the urologist preference variable. Table 3 presents prespecified subgroup analyses using the same analytical approaches in Table 2 , in men with lower-risk disease and in men with high-risk disease. In both subgroups, the multivariable regression models demonstrated an increased risk of prostate cancer-specific mortality associated with use of primary ADT, which was particularly pronounced in the group with lower-risk disease. For both groups using the instrumental variable approaches, there were trends toward reduction in prostate cancer-specific mortality, with a statistically significant reduction only in the high-risk subgroup using urologist preference as the instrument. In the lower-risk group, the instrumental variable approaches demonstrated no significant effect on overall mortality. In the high-risk group, there was a significant reduction in overall mortality using urologist preference for primary ADT as the instrument.
RESULTS
DISCUSSION
This study examined the association between use of primary ADT and survival in men with prostate cancer using both standard multivariable regression and instrumental variable approaches. Most notably, there was a sharp contrast in results between the different approaches, particularly with regard to prostate cancer-specific mortality. The standard multivariable regression approaches uniformly showed an increased risk of prostate cancer-related death. Both instrumental variable approaches demonstrated trends toward a protective effect of primary ADT, although results were statistically significant only for urologist preference. In the high-risk disease subgroup, using urologist preference for primary ADT as the instrument, there was a significant reduction in overall mortality, driven by the large reduction in prostate cancer-specific mortality. Several points support the validity of the results from the instrumental variable approaches. The results are consistent with those from clinical trials on primary ADT use in men with locally advanced or metastatic prostate cancer, which have demonstrated a clear reduction in prostate cancer-specific mortality, with initial results from the Medical Research Council study showing improvement in overall survival as well. 30, 31 The results are biologically plausible, with the beneficial effect of primary ADT being mediated through a reduction in prostate cancer-specific mortality. Multivariable regression analyses in this study and in other published works examining the use of primary ADT have uniformly shown an increased risk of prostate cancer-specific mortality in localized disease, 21, 23 almost certainly representing insufficient control of indication bias. One likely candidate for an unmeasured confounder in previous analyses is prostate-specific antigen level at diagnosis (which until recently was unavailable in the SEER-Medicare dataset), which is both a strong driver of decisions to use ADT and an important prognostic factor. Important assumptions about the instruments used in this study are likely to be valid. The assumption that the instruments are not independently related to the outcome cannot be tested directly. However, by theoretical considerations, geographic region as defined by HSA is unlikely to have an independent effect on prostate cancerspecific mortality. There is potentially more concern with use of an instrument based on the treating urologist. However, as we limited our analysis to patients who did not undergo definitive treatment such as surgery or radiation, and as dosing regimens for ADT are generally standard, any effect of the urologist should only be mediated through their decision to use ADT, which would not violate the assumption. In addition, stratification by categories of the instruments yielded a good balance of relevant prognostic factors (Table 1) . We have also demonstrated in this study and in previous work that both our instruments are very strongly correlated with use of primary ADT, an important criterion for an instrumental variable. 19, 20 A final point is that the pattern of results was consistent across the 2 different instruments, providing further credibility for the validity of our findings.
There are a number of methodological issues of note in this study. The choice of instrument can be important. Although results were similar across the instruments, urologist preference has potential advantages over HSA. Statistical power is often very limited in instrumental variable analyses, with low precision of point estimates rendering meaningful interpretation of results difficult, as demonstrated in a recent paper examining the impact of radical prostatectomy for localized prostate cancer. 32 The precision of an instrumental variable analysis appears to depend on the number of units for the instrument, rather than on the patient sample size, and also on the strength of the instrument in terms of its association with the exposure of interest. In this study, there were 81 HSAs versus 1321 urologists, and in previous work we have shown that, through the period of the study, the urologist of the patient was the strongest predictor of whether the patient received ADT. 20 As such, there was more statistical power using urologist preference as the instrument, as can be noted by the narrower confidence intervals. This resulted in some of the findings being statistically significant using urologist preference as the instrument, which were not significant using HSA, despite close point estimates ( Table 2) . Another methodological issue is the choice of estimation method for the instrumental variable analysis. A previous study using SEER-Medicare data and an instrumental variable approach also examined primary ADT and survival. 9 That study also used the proportion of patients receiving primary ADT within the HSA as the instrument, but used a different analytical approach, based on the Rubin Causal model. 33 Although the results were similar to our findings, there was an increased risk for prostate cancer-specific mortality associated with the instrument among low-risk patients; in the high-risk group, the protective effect was more modest such that there was no effect on overall mortality. The authors explained the adverse effect on prostate cancer-related death in the lower-risk group as being potentially related to the selection of more androgen-resistant clones in the setting of ADT. However, as pointed out by others, 34 a more plausible explanation is simply residual confounding by indication. In the lower-risk group, it is more likely that unmeasured factors accounted for the decision to use ADT, making the indication bias much stronger. As we used a similar instrument and the same database, it is evident that the difference in results must be related to our use of a different estimation method, which appears to have allowed for better control of bias. This study has important limitations. With an observational design, it is not possible to determine with certainty what the "true" effect of ADT is on survival and therefore know whether the findings from our instrumental variable analyses provide a more correct assessment than those from the standard multivariable regression methods. However, we have argued that the instrumental variable analyses are more likely to be correct as they produced findings that are more in line with biological plausibility. In addition, known prognostic variables were better balanced across categories of the instruments, making it more likely that important unmeasured factors would also be better balanced. An important limitation of the instrumental variable approach in general is the difficulty in finding suitable instruments. This requires a clinical context in which decisions to treat are highly dependent on nonclinical factors. In this study example, we used an era in which there was extreme variation in use of ADT, 20 likely not only because of uncertainty about its efficacy but also because of tremendous financial incentives for its use (to which physicians respond variably). Major cuts in reimbursement since 2004 may have substantially reduced physician variation in use of ADT, making physician preference a weaker instrument in more recent years. 35 Finally, the interpretation of results from instrumental variable analyses is not straightforward, as they estimate the average effect in the so-called "marginal population"-those patients in whom treatment assignment depends entirely on the instrument. In our example, the findings would not apply to patients who would "always" or "never" receive ADT, regardless of the instrument. Given the substantial clinical uncertainty about use of ADT during the study period, however, a large proportion of patients would be expected to fall within the marginal population. Nevertheless, it may be difficult for a practicing clinician to identify whether an individual patient under his or her care is a member of the marginal population and therefore whether the study results would apply to them. Instrumental variable analyses are therefore often most useful for determining population level effects of policy changes. 36 In this context, for example, the study results may help inform the potential impact of policies that reduce reimbursement for ADT.
The study findings have a number of implications. From a clinical standpoint, with the caveats in interpretation discussed above, our results suggest that there may be no overall survival benefit in use of primary ADT for lower-risk prostate tumors, despite a modest reduction in prostate cancer-specific mortality. In contrast, in the high-risk subgroup, our results provide support for use of primary ADT as compared with observation. However, recent clinical trial results suggest that for those men who can tolerate it the optimal approach for high-risk disease may be radiation combined with ADT. 37 From a methodological standpoint, instrumental variable analysis appears to be a powerful tool for reducing bias in the assessment of treatment effectiveness using observational data. Even when clinical trial data are already available, the results of a confirmatory instrumental variable analysis can be helpful. Results based on observational data, which usually include less-selected populations, may in fact provide a truer assessment of treatment effectiveness as compared with clinical trials. 5 Our results also demonstrate that careful consideration should be paid to the choice of instrument and the estimation method as these can have important effects on the findings.
